Programme

Overview: This session will explore what “good enough” means in modern radiotherapy, spanning technological uncertainties, clinical and radiobiological evidence generation and daily clinical practice. It will examine how advances in imaging, planning and treatment delivery may reduce some uncertainties while redistributing others, and why margins or probabilistic approaches in treatment planning will remain essential to ensure reliable dose delivery. It will highlight the importance of accurate and robust predictive models for “good enough” treatments and how patient-centred goals can guide safe, timely and meaningful care. Finally, the session will address the persistent gap between evidence, access and innovation.

Overview: This symposium explores how innovation is reshaping radiotherapy across the entire clinical pathway. It begins with multimodality imaging, highlighting the practical integration of MRI and other advanced imaging techniques to enhance precision in treatment planning. The focus then shifts to the evolving role of RTTs, examining how AI and automation are transforming clinical tasks into more evaluative and decision-driven responsibilities. Finally, implementation of simulator-free radiotherapy demonstrates how these advances translate into streamlined, patient-centred workflows. Together, these sessions provide a cohesive perspective on how technology, workforce evolution, and workflow redesign are driving the future of radiotherapy practice.

Overview: The growing availability of high-quality international guidelines (e.g., European Society for Radiotherapy and Oncology, American Society of Clinical Oncology) • The persistent gap between evidence-based recommendations and real-world clinical practice • Key barriers to implementation: Resource limitations, Health system constraints, Human and organizational factors • Global disparities in radiotherapy access and infrastructure • The importance of resource-adapted guidelines for different healthcare settings • The emerging role of implementation science, digital tools, and AI in improving adherence • A proposed multi-level implementation model (global → national → institutional) • The need for stronger involvement of international societies in supporting implementation • Key message: Guidelines should be evaluated based on patient benefit, not publication impact

Overview: This session will focus on the role of metastases-directed therapy in the form of stereotactic ablative body radiotherapy in the treatment of oligometastatic breast and gynaecological malignancies. Ongoing and future studies will be summarised. Selection criteria will be presented emphasising the importance of considering varying biological subtypes. Decision-making around how to integrate local therapy with systemic therapies will be addressed. Importantly this symposium will include the patient's perspective to better understand what is most important to patients in terms of treatment goals and unmet needs.